<DOC>
	<DOCNO>NCT02942043</DOCNO>
	<brief_summary>The purpose study explore efficacy safety different dos bevacizumab injection treatment malignant pleural effusion patient advance non-squamous non-small cell lung cancer .</brief_summary>
	<brief_title>Bevacizumab Treatment Malignant Pleural Effusions Non-squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This study prospective , multicenter , randomize , phase II clinical study . 87 patient recruit . Group A ( low dose group ) Intrapleural injection bevacizumab 2.5mg/kg/times , d1 , d8 ; 21 day course treatment . Subjects receive two course treatment termination treatment list standard . Group B ( medium dose group ) Intrapleural injection bevacizumab 5mg/kg/times , d1 , d8 ; 21 day course treatment . Subjects receive two course treatment termination treatment list standard . Group C ( high dose group ) Intrapleural injection bevacizumab 7.5mg/kg/times , d1 , d8 ; 21 day course treatment . Subjects receive two course treatment termination treatment list standard . Main evaluation criterion : pleural effusion objective response rate ( ORR ) ( WHO standard ) Secondary evaluation criterion : pleural fluid time progression ( TTP ) , overall survival ( OS ) , ORR , QOL score ( Quality Life Questionnaire-lung cancer ) KPS , safety ( NCI CTCAE V4.03 )</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Voluntarily sign informed consent ; 2 . Nonsquamous nonsmall cell lung cancer , newly diagnose previously treat systemic chemotherapy / epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor treatment ; 3 . B ultrasound , chest Xray CT examination large number pleural effusion , cytology confirm malignant pleural effusion ; 4 . Aged 1875 year ; 5 . Eastern Cooperative Oncology Group ( ECOG ) score ≤ 2 ; 6 . Survival expect exceed 8 week If follow criterion meet , subject shall exclude : 1 . Squamous cell carcinoma ( include adenosquamous carcinoma ) small cell lung cancer ( include small cell carcinoma nonsmall cell mixed lung cancer ) ; 2 . In past 2 week , systematic antitumor treatment include chemotherapy ( include thoracic chemotherapy ) , radiotherapy ( exclude radiotherapy metastatic lesion outside thoracic radiation field ) , target therapy , immunotherapy biotherapy ; 3 . The subject receive antivascular endothelial growth factor ( VEGF ) small molecule tyrosine kinase inhibitor monoclonal antibody past 4 week ; 4 . The subject participate clinical trial past 4 week ; 5 . The subject previously receive bevacizumab pleural perfusion therapy ; 6 . Laboratory result : White blood cell count &lt; 3 × 109 / L , neutrophil count &lt; 1.5 × 109 / L , platelet &lt; 75 × 109 / L , hemoglobin &lt; 8g / dL ; Coagulation abnormality ( INR &gt; 1.5 prothrombin time ( PT ) &gt; ULN + 4 second activate partial thromboplastin time ( APTT ) &gt; 1.5 ULN ) , bleed tendency treat thrombolysis anticoagulation ; Serum total bilirubin ≥1.5 ULN ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 2.5 ULN absence liver metastasis ; ALT AST ≥5 ULN liver metastasis ; Serum albumin &lt; 30g / L ; Serum creatinine ≥ 1.5 ULN creatinine clearance &lt; 40ml / min ; Urine routine urinary protein ≥ ++ , 24 hour urine protein ≥ 1.0 g ; 7 . Hypertension control drug ; 8 . Heart disease significant clinical symptom , : congestive heart failure , coronary heart disease symptom , arrhythmia hardly control drug , myocardial infarction 6 month , heart failure ; 9 . Imaging ( CT MRI ) show tumor lesion 5 mm away large vessel , presence invasive central vasculature central tumor ; image ( CT MRI ) show significant cavitation necrosis lung tumor ; Other disease may cause haemoptysis ; 10 . Imaging ( CT chest radiograph ) show significant pneumothorax , fluid pneumothorax ; 11 . Bilateral pleural cavity large number effusion encapsulate pleural effusion ; 12 . Obvious cough blood 6 month , daily hemoptysis amount half teaspoon ( 2.5ml ) ; 13 . Significant bleeding symptom definite bleed tendency within 12 month randomization , gastrointestinal bleeding , hemorrhagic gastric ulcer , occult blood ++ , intracerebral hemorrhage , vasculitis , congenital acquire coagulopathy disorder ; 14 . Thrombosis , cancer thrombosis ( include arteriovenous thrombosis , tumor thrombus , pulmonary embolism , transient ischemic attack , etc . ) occur within 12 month ; 15 . There gastrointestinal obstruction , peptic ulcer , Crohn 's disease , ulcerative colitis gastrointestinal disease disease may cause gastrointestinal bleeding perforation ; 16 . Severe respiratory disease , need longterm oxygen , corticosteroid treatment diseases chronic obstructive pulmonary disease , interstitial lung disease respiratory failure ; 17 . The toxicity previous antineoplastic therapy yet recover grade 2 fully recover ; 18 . Patients uncontrolled central nervous system metastasis ; 19 . There serious uncontrolled systemic disease , nephrotic syndrome , infection , poorly control diabetes ; 20 . Patients active HIV（human immunodeficiency virus） , HBV（hepatitis B virus） , HCV（hepatitis C virus） infection ; 21 . Patients undergone surgery ( &lt; 28 day ) heal completely , unhealed wound study ; 22 . Patients know allergic bevacizumab component drug ; 23 . Pregnant lactate female patient , unwilling take contraceptive measure reproductive age patient ( include men ) ; 24 . There serious psychological mental abnormality , lack compliance ; 25 . The investigator determines circumstance may affect conduct clinical study determination finding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Malignant pleural effusion</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>